Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Serum Level of Interleukin 36 in Patients With Multiple Sclerosis Publisher Pubmed



Alsahebfosoul F1 ; Jahanbaniardakani H2 ; Ghavimi R3 ; Sedaghat N1 ; Etemadifar M4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Isfahan Medical Students Research Center (IMSRC), Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Pharmaceutical Biotechnology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Immunoassay and Immunochemistry Published:2018


Abstract

Introduction: Multiple sclerosis is a chronic autoimmune demyelinating disorder of central nervous system with unknown origin. In MS disease, T cells are pointed to myelin antigens and it leads to myelin loss and axonal degeneration. Cytokines are important regulators of immune system and has critical roles in MS pathogenesis. Interleukin 36, a member of interleukin 1 family, has been shown having important roles in some autoimmune disorders due to its proinflammatory actions and its role in host immunity. Methods and materials: In the current study, 49 relapsing remitting multiple sclerosis patients and 41 healthy individuals were recruited. IL36 measurement was performed using enzyme-linked immunosorbent assay technique. Results: Mean age of RRMS patient and control group were 31.84 ± 6.89 and 34.27 ± 8.83 years, respectively. Serum level of IL36 were 61.91 ± 16.29 in MS patients and 42.26 ± 17.54 in healthy group (P < 0.001). Conclusion: in this study for the first time, significantly higher serum level of IL36 was determined in RRMS patients comparing healthy individuals. This data may suggest important roles of this cytokine in MS pathogenesis. © 2018, © 2018 Taylor & Francis.
Related Docs
View other Related Docs
1. Elevated Serum Level of Il-4 in Neuromyelitis Optica and Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)
2. Interleukin 18 Polymorphisms and Its Serum Level in Patients With Multiple Sclerosis, Annals of Indian Academy of Neurology (2019)
3. Decreased Serum Levels of Interleukin-35 Among Multiple Sclerosis Patients May Be Related to Disease Progression, Journal of Biological Regulators and Homeostatic Agents (2018)
4. Il-23 Plasma Level Measurement in Relapsing Remitting Multiple Sclerosis (Rrms) Patients Compared to Healthy Subjects, Immunological Investigations (2015)
5. Il-27 Plasma Level in Relapsing Remitting Multiple Sclerosis Subjects: The Double-Faced Cytokine, Journal of Immunoassay and Immunochemistry (2016)
6. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)
7. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
8. Increased Serum Level of Il-37 in Patients With Multiple Sclerosis and Neuromyelitis Optica, Acta Neurologica Belgica (2015)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (119)
Vahid Shaygannejad (98)
Other Related Docs
9. High-Resolution Melting Curve Analysis of Polymorphisms Within Cd58, Cd226, Hla-G Genes and Association With Multiple Sclerosis Susceptibility in a Subset of Iranian Population: A Case–Control Study, Acta Neurologica Belgica (2020)
10. Evaluation of Plasma Osteopontin Level in Relapsing- Remitting Multiple Sclerosis Patients Compared to Healthy Subjects in Isfahan Province, International Journal of Neuroscience (2020)
11. Comparison of Ox40 Expression in Patients With Multiple Sclerosis and Neuromyelitis Optica As an Approach to Diagnosis, Allergy, Asthma and Clinical Immunology (2023)
12. Expression and Clinical Significance of Il7r, Nfatc2, and Rnf213 in Familial and Sporadic Multiple Sclerosis, Scientific Reports (2021)
13. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy, Cell Journal (2017)
14. Association of Interleukin-1 Gene Cluster Polymorphisms and Haplotypes With Multiple Sclerosis in an Iranian Population, Journal of Neuroimmunology (2015)
15. The Levels of Soluble Forms of Cd21 and Cd83 in Multiple Sclerosis, Journal of Neuroimmunology (2018)
16. Multiple Sclerosis and Cerebral Endothelial Dysfunction: Mechanisms, Pathophysiology (2011)
17. Evaluation of Matrix Metalloproteinase-9 Plasma Levels in Untreated New Relapsing–Remitting Multiple Sclerosis Patients and Their First-Degree Family, Metabolic Brain Disease (2021)
18. Correlation of Midkine Serum Level With Pro- and Anti-Inflamatory Cytokines in Multiple Sclerosis, Iranian Journal of Immunology (2014)
19. The Role of Immune Regulatory Molecules in Multiple Sclerosis, Journal of Neuroimmunology (2019)
20. Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta, Iranian Journal of Allergy, Asthma and Immunology (2020)
21. Toll Like Receptor 2 and 4 Expression in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients, Iranian Journal of Immunology (2014)
22. Cytomegalovirus and Varicella Zoster Virus Seropositivity of Iranian Patients With Multiple Sclerosis: A Population-Based Study, Journal of Neuroimmunology (2017)
23. Mannose-Binding Lectin Mediated Complement Pathway in Autoimmune Neurological Disorders, Iranian Journal of Allergy, Asthma and Immunology (2016)
24. Childhood-Onset Multiple Sclerosis: Report of 82 Patients From Isfahan, Iran, Archives of Iranian Medicine (2007)
25. Evaluation of Soluble Human Leukocyte Antigen-G (Shla-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2015)
26. Evaluating the Effects of Epigallocatechin-3-Gallate on Hif-1Α Protein and Rorc Gene Expression in Peripheral Blood Mononuclear Cells in Patients With Multiple Sclerosis, Basic and Clinical Neuroscience (2021)
27. Cd24 Gene Allele Variation Is Not Associated With Oligoclonal Igg Bands and Igg Index of Multiple Sclerosis Patients, NeuroImmunoModulation (2012)
28. The Effect of Ifn-Β Treatment on Plasma Levels of Bdnf and Il-6 in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2021)
29. Cerebrospinal Fluid and Serum Markers of Inflammation in Patients With Multiple Sclerosis, Advances in Neuroimmune Biology (2017)
30. Multiple Sclerosis: Clinical Features, Pathophysiology, Neuroimaging and Future Therapies, Future Neurology (2009)
31. Association of Helicobacter Pylori With Multiple Sclerosis: Protective or Risk Factor?, Current Journal of Neurology (2020)
32. Chlamydia Pneumoniae Seropositivity in Iranian Patients With Multiple Sclerosis: A Pilot Study; [Obecnosc Przeciwcial Przeciw Chlamydia Pneumoniae Wsrod Iranskich Chorych Na Stwardnienie Rozsiane: Badanie Pilotazowe], Neurologia i Neurochirurgia Polska (2011)
33. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
34. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
35. Higher Latitude Is Significantly Associated With an Earlier Age of Disease Onset in Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2016)
36. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
37. Prevalence of Familial Multiple Sclerosis in Isfahan, Iran, Journal of Isfahan Medical School (2011)
38. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
39. Prognostic Value of Intrathecal Igg Synthesis in Multiple Sclerosis: A Study in 54 Patients, Tehran University Medical Journal (2008)
40. Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges, CNS and Neurological Disorders - Drug Targets (2018)
41. The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group, Journal of Isfahan Medical School (2013)
42. Can Plasma Exchange Therapy Induce Regulatory T Lymphocytes in Multiple Sclerosis Patients?, Clinical and Experimental Immunology (2012)
43. Evaluation of Plasma Soluble Cd137 Level in Relapsing-Remitting Multiple Sclerosis Patients in Comparison With Healthy Controls in Isfahan Province, Iran, Neurology Asia (2020)
44. Association of Dietary Patterns With Systemic Inflammation, Quality of Life, Disease Severity, Relapse Rate, Severity of Fatigue and Anthropometric Measurements in Ms Patients, Nutritional Neuroscience (2020)
45. Elevated Csf Concentration of Ccl3 and Ccl4 in Relapsing Remitting Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)
46. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
47. Investigation of Erg Gene Expression in Iranian Patients With Multiple Sclerosis, Immunological Investigations (2018)
48. Early Clinical Response and Complications of Therapeutic Plasma Exchange in Central Nervous System Demyelinating Diseases, Journal of Central Nervous System Disease (2024)
49. The Frequency of Varicella-Zoster Virus Infection in Patients With Multiple Sclerosis Receiving Fingolimod, Journal of Neuroimmunology (2019)
50. Demographic and Clinical Characteristics of Familial and Sporadic Multiple Sclerosis Patients, International Journal of Preventive Medicine (2023)